Gastroenterology
News
IBD patients have limited protection against Omicron with third vaccine dose
Patients with IBD taking infliximab or tofacitinib may be more vulnerable to Omicron infection even after a third dose of a COVID-19 mRNA vaccine...
From the Journals
Vonoprazan triple therapy most cost-effective for H. pylori: Study
Rifabutin triple therapy (Talicia) is the second most cost-effective strategy for H. pylori eradication.
From the Journals
Kiwifruit found effective for constipation
Fiber found in kiwifruit cell walls swells and holds water, which can soften stools and increase stool frequency.
From the Journals
Study says food dye red 40 can trigger bowel problems
The dye is also known as FD&C Red 40 and Food Red 17.
From the Journals
FMT doesn’t appear to affect weight loss after bariatric surgery
There is much interest in the gut microbiota as a potential target for the treatment of obesity. FMT from a lean donor has shown promise in...
From the Journals
Nonheavy alcohol use associated with liver fibrosis, NASH
“Our results call this strict categorization into question, suggesting that even nonheavy alcohol use should be considered as a factor...
From the Journals
Lifestyle guidance app may be effective in NASH
“The widespread use of smartphones, which can process and communicate data in real time, makes them an ideal platform for therapeutic...
From the Journals
Dietary interventions can support IBD treatment
“The Internet has a dizzying array of diet variants touted to benefit inflammation and IBD, which has led to much confusion among patients, and...
Commentary
Debating the clinical trial upending colonoscopy practices
“But I feel like this study reinforces my feeling that we ought to be presenting these [options], and not saying one is superior or inferior to...
News from the FDA/CDC
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Data for Idacio (adalimumab-aacf) showed safety, efficacy, and immunogenicity similar to Humira.
From the Journals
Liver cancer exacts high financial toll on older adults
In the first year after a hepatocellular carcinoma diagnosis median Medicare payments exceed $65,000.